(August 9, 2017) The International Journal of Cancer recently published an article on preliminary findings for two factors that influence one’s risk of ovarian cancer, namely the age at which a woman gives birth and the age at which she starts using oral contraceptives. The authors, including Celeste Leigh Pearce, PhD of OCRFA’s Scientific Advisory Committee, studied data on almost 4,000 women, and found that women who had their first child after 35 had a 47% lower risk of developing ovarian cancer than women who had their first child before 25 years of age. Additionally, for every 5 years a woman waited to give birth for the first time, the risk was reduced by thirteen percent. They also found that women using oral contraceptives before the age of 35 had greater protection from ovarian cancer than those who started at a later age. Current and previous data support the fact that the effects seen from later births last for at least 30 years after the last time a woman gave birth. However, the effects seen from earlier use of oral contraceptives need further study as not all data comes to the same conclusion.
Related Topics
OCRA Sponsors NCCN Guidelines for Cervical, Ovarian, and Uterine Cancer Patients
This article was updated in April 2026 to reflect NCCN’s release of the 2026 Guidelines for Uterine Cancer Patients. OCRA is a proud sponsor of the 2026 Patient Guidelines for Cervical Cancer and Uterine Cancer, and the 2025 Patient Guidelines for Ovarian. We believe ensuring access to clear, understandable information is critical. NCCN provides wonderful … Continued
FDA Approves Lifyorli Plus Abraxane for Platinum-Resistant Ovarian Cancer
On March 25, 2026, the U.S. Food and Drug Administration (FDA) approved Lifyorli (relacorilant), made by Corcept Therapeutics, in combination with Abraxane (nab-paclitaxel) for adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior lines of treatment, including prior Avastin (bevacizumab). The approval follows last month’s FDA … Continued
The Overview: March 2026
OCRA’s Annual Advocacy Day Draws Survivors and Caregivers from Across the Country More than 120 gynecologic cancer survivors, caregivers, researchers and supporters from nearly forty states filled the halls of the U.S. Capitol on Tuesday, March 17—dressed in teal, the color of ovarian cancer awareness—as Ovarian Cancer Research Alliance (OCRA) held its annual Spring Advocacy Day. The … Continued